SAN MATEO, Calif., Nov. 5 /PRNewswire/ -- In a survey of 100 infectious disease specialists following last week's ICAAC/IDSA Annual Meeting, Merck was perceived as standing out above other companies at the conference, while Tibotec Therapeutics was perceived as having the best overall image in infectious disease. GlaxoSmithKline, Pfizer and Cubist Pharmaceuticals rounded out the top companies in overall image among the specialists.
The 2008 ICAAC/IDSA Annual meeting -- one of the largest meetings attended by infectious disease specialists -- was held from October 25-28 in Washington D.C. AlphaDetail conducted a brief AlphaPulse(TM) survey of 100 infectious disease specialists to gauge physician reaction to data presented at the meeting. Of the respondents, half attended the 2008 meeting.
When asked their opinion about what the most important data presented
at this year's conference was, nearly half of the respondents cited topics
focused on HIV, particularly findings in initiating earlier treatment, the
approval of a new dosing regimen for Prezista in naive patients, and data
about newer HIV treatments showing promise as 1st line therapies. New MRSA
data was also cited frequently.
"There was new data presented on HIV treatment regarding use of either
Prezista or raltegravir as first-line agents".
-- Infectious Disease Specialist, 11/08
When prompted with data presented at the conference, the majority of respondents revealed that the most important study indicated a 70% improvement in survival for patients who initiated HAART therapy with CD4 counts between 351 and 500 vs. those who initiated at 350 and below. Interestingly, a large percentage of respondents also highlighted key findings about a compound (TMC207) as important news that they were not familiar with prior to the meeting.
To receive the full AlphaPulse(TM) report at no charge, please contact
Bob Latshaw at (2
|SOURCE AlphaDetail, Inc.|
Copyright©2008 PR Newswire.
All rights reserved